Testing a person's own fat-derived cells for type 2 diabetes
Tests fat-derived cells from the patient's own body in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Autologous SVF Therapy for Type 2 Diabetes
Key facts
- Where
- São Jose Do Rio Preto, BrazilSee the site
Where in Brazil
- Kaiser ClinicaSão Jose Do Rio Preto, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kaiser Clinic and Hospital
- Trial code
- NCT07487467
- Record updated
- 23 March 2026
- Original description
This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM).Read full original descriptionShow less
Evaluation of Autologous Adipose-Derived Stromal Vascular Fraction Obtained by 1210-nm Laser Photostimulation for the Treatment of Type 2 Diabetes Mellitus
This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM).
Adipose tissue will be harvested using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method), followed by centrifugation without enzymatic digestion. The isolated SVF will be injected endoluminally into the duodenal submucosa during the same surgical procedure.
Five adult patients with T2DM will be followed for six months to assess metabolic control, pancreatic function, and quality of life outcomes.
Inclusion: Age ≥ 18 years; Both sexes; Diagnosis of Type 2 Diabetes Mellitus for less than 10 years; BMI ≥ 25 kg/m²; HbA1c between 7.5% and 9.5%; C-peptide > 1.0 nmol/L; Use of metformin and/or pioglitazone, with or without sulfonylurea.
Exclusion: Positive anti-GAD antibodies; Use of insulin therapy; Use of SGLT2 inhibitors; Use of DPP-4 inhibitors; Type 1 Diabetes Mellitus or autoimmune diabetes; Unknown duration of diabetes; Pregnancy or breastfeeding; Use of GLP-1 receptor agonists.